The Marriott Marquis San Diego

It was my pleasure last week to attend the annual PLUS Conference, this year held in San Diego. It was great to be back at a live PLUS event again and to see so many colleagues from around the industry. As always, the PLUS staff did an amazing job organizing the event, and the turnout was great as well. It was also great to be back in San Diego. It was a little bit cool and it rained on Tuesday but despite that San Diego was still beautiful. It was great to see many old friends and to make new friends as well. Continue Reading PLUS Conference in San Diego

Peter S. Selvin

In the following guest post, Peter S. Selvin, a partner with Beverly Hills, California based Ervin, Cohen & Jessup law firm where he chairs the firm’s insurance coverage and recovery practice, reviews two recent case decisions involving the question of whether or not D&O insurance policies apply to provide coverage for consumer protection claims arising from the sale or marketing of products. A version of this article previously published in the Los Angeles Daily Journal. I would like to thank Peter for allowing me to publish his article as a guest post on this site. I welcome guest post submissions from responsible authors on topics of interest to this blog’s readers. Please contact me directly if you would like to submit a guest post. Here is Peter’s article. Continue Reading Guest Post:  Are Consumer Protection or False Advertising Claims Covered by Insurance?

One litigation trend that I have been following on this site since the initial coronavirus outbreak in the U.S. in March 2020 is the incidence of COVID-19-related securities class action litigation. Even though the outbreak is now well into its third year, these coronavirus-related cases continue to be filed. In the latest example of this phenomenon, on November 8, 2022, a plaintiff shareholder filed a securities class action lawsuit against Eiger Biopharmaceuticals in connection with the company’s efforts to develop a COVID-19 treatment. A copy of the plaintiff’s complaint in the case can be found here. Continue Reading Biopharma Company Hit with COVID-Related Securities Suit

As I noted in recent posts (for example, here), an anti-ESG backlash has been forming. The backlash has already taken a variety of forms, including anti-ESG legislation and anti-ESG litigation. Now, in what one media source called a “new front in a campaign against companies” related to ESG activities, a group of five Republican senators has sent letters to 51 large U.S. law firms warning the firms that the Senators plan to use their congressional oversight powers “to scrutinize the institutionalized antitrust violations being committed in the name of ESG.” The Senators’ letter campaign is described in a November 4, 2022 Reuters article (here). The Senators’ November 3, 2022 letters to the law firms can be found here. Continue Reading Senators Warn Law Firms Concerning ESG-Related Advice

The hot button topic in both the investing world and the D&O insurance world these days is “ESG.” Setting aside the fundamental problem that nobody actually knows what ESG is, there is the inextricably related problem that the D&O claims risk related to ESG is fundamentally misunderstood. The current basic premise in the D&O insurance world is that companies that are “good” on ESG (whatever that means) represent better D&O insurance risks. Yet, as I have documented in numerous posts on this site (most recently here), it is not the ESG laggards that are getting hit with D&O claims; the claims are in fact being filed against companies that are proactive on ESG issues.

 

The latest example of this phenomenon is the securities class action lawsuit filed late last week against wood products company Enviva, which promotes itself as growth-oriented environmental, social, and governance (ESG) company. The lawsuit follows publication of a short seller report that, among other things, characterized the company as “the latest ESG farce” engaged in “textbook greenwashing.” A copy of the November 3, 2022 complaint against Enviva can be found here. Continue Reading Wood Products Company Hit with ESG “Greenwashing” Securities Suit

On October 26, 2022, the SEC adopted final rules implementing the Dodd-Frank Act’s requirement for issuers to recover from current and former executives compensation that was erroneously paid due to an accounting restatement. The final rules require securities exchanges to adopt listing standards that will require listed companies to implement and disclose policies requiring the erroneously paid compensation to be recovered, on a “no fault” basis – that is, without regard to whether any misconduct occurred or whether an executive bears responsibility. The SEC’s Release covers a broad range of topics, including — importantly for readers of this blog — considerations relating to indemnification or insurance for the clawed-back compensation. The SEC’s October 26, 2022 press release about the new rules can be found here. The SEC’s fact sheet about the new rules can be found here. The SEC’s Release document (referred to below as the “Release”) can be found here. Continue Reading Insurance Implications of the SEC’s New Compensation Clawback Rules

One of the more noteworthy developments in recent years has been the increasing frequency of collective investor actions outside the U.S. In certain instances, these cases have resulted in settlements that rival the largest U.S. securities class action lawsuit settlements in size. The largest of the settlements outside the U.S. are compiled in an October 31, 2022 report from ISS Securities Class Action Services entitled “The Top 25 Non-North American Settlements: Largest Securities-Related Settlements Outside of North America of All-Time.” The report, which updates ISS SCAS’s earlier research and was written by Jeff Lubitz, Managing Director, ISS Securities Class Action Services, and Jarett Sena, Director of Litigation Analysis, ISS Securities Class Action Services, can be found here. Continue Reading The Top 25 Collective Investor Action Settlements Outside of North America

In the current difficult business environment, many businesses face a broad array of daunting business challenges, including economic inflation, rising interest rates, supply chain and labor supply disruptions, the continuing threat of COVID-19 shutdowns, and the war in Ukraine. These various circumstances not only represent potential operational hurdles they may also involve increased litigation risk as well – as I have noted on previous posts (for example, here) these various business challenges can translate into litigation, as well. In the latest example of this phenomenon, earlier this week a plaintiff shareholder launched a securities class action lawsuit against the healthcare apparel firm FIGS, Inc. relating to the increased supply chain costs the company experienced since its June 2021 IPO. A copy of the November 1, 2022 complaint against the company can be found here. Continue Reading Apparel Company Hit with Supply Chain-Related Securities Lawsuit

In numerous prior posts I have examined efforts by plaintiffs’ attorneys to try to impose civil liability on corporate executives in D&O claims following cyber security incidents. Two recent cases show that, in addition to potential civil litigation liability exposure, corporate executives may also face potential regulatory liability and even criminal liability exposure for cyber security incidents at their company. The two recent cases are discussed in an October 27, 2022 memo from the White and Case law firm, here. Continue Reading Corporate Executives Face Personal Liability Exposure for Cyber Incidents

As I have previously noted (most recently here), something of an anti-ESG backlash has started to take shape, at least in certain quarters. Legislatures in several states have passed legislation prohibiting state pension funds from investing in ESG- focused investments or prohibiting the state from doing business with companies that boycott certain industries. The backlash has also taken the form of litigation, as, for example, with respect to the lawsuit recently filed against Starbucks board pertaining to the company’s diversity, equity, and inclusion initiative (DEI).

 

As Alison Frankel discusses in an October 26, 2022 post on her On the Case blog (here), and in the latest manifestation of this kind of anti-ESG litigation, a nonprofit group has filed an action against the pharmaceutical giant Pfizer based on the company’s sponsorship of a foundation offering fellowships aimed at Black, Latino, Native American and other minority candidates. This latest lawsuit is yet another indication that the companies that get caught up in ESG litigation may the companies taking ESG initiatives, perhaps more so that ESG laggards. Continue Reading Suits Targeting Firms Seeking to Boost Minorities Highlight ESG Risks